Purified Proteins
Animal Serum Products
Enzymes
Clotting Proteins
Placenta Extracts
Dried Animal Blood Products
Animal Glands & Organs
News


September 17, 2010
Freeze Drying Available

Large Scale Freeze Drying

Bovogen Biologicals has recently completed the commissioning of a 1000 litre ice capacity lyophiliser (freeze dryer) in its manufacturing site in Melbourne. This provides the company with the capability to manufacture larger batch sizes of its existing product range which few other related companies have. Bovogen Biologicals has also constructed a clean room manufacturing area to provide a hygienic environment for the processing of manufactured lyophilised products. This large scale lyophiliser is also available for contract freeze drying services.

For more information contact Bovogen Biologicals.


July 17, 2010
Fibrinogen Certificate Granted

Fibrinogen EDQM Certificate

Bovogen Biologicals is pleased to announce it has received European Directorate of Quality Medicines (EDQM) certification for its purified bovine fibrinogen. This will now enable customers to use this highly purified protein for medicinal applications. To the company's knowledge, no other fibrinogen manufacturer globally has attained EDQM certification for this product.

See Bovogen Biologicals' range of products.


June 17, 2010
Trypsin Powder Available

Trypsin in Australia

Bovogen Biologicals Pty Ltd is now manufacturing a high quality 1:250 lyophilized Trypsin sourced from Australian origin porcine pancreas glands. Both Standard and Premium Cell Culture Grades of Trypsin powder are available as stock formats. In addition, Bovogen Biologicals is able to offer variant Porcine or Bovine Trypsin products to agreed customer specifications.

See Bovogen Biologicals for more information on Trypsin and our range of products.


March 17, 2010
Bovogen Biologicals Distributor

Interpath Services Australian Distributor

Bovogen Biologicals are pleased to announce that they have appointed Interpath Services Pty Ltd as their exclusive Australian distributor. Interpath Services Pty Ltd is a highly regarded Australian supplier. Established in 1989, they offer a team of experienced and commited professionals who excel in the service that they provide to their customers.

We are very much looking forward to working together in the Australian market and have every confidence that our partnership will be of great benefit to our customers. Bovogen Biologicals has a range of informnation on Foetal Bovine Serum (FBS) and other products.


August 17, 2008
Foetal Bovine Serum Certificate

FBS EDQM Certificate of Suitability Granted

Bovogen Biologicals received a Certificate of Suitability from the European Directorate of Quality Medicines for it's range of Australian origin foetal bovine serum (FBS) products in June, 2008. This certification meets the criteria described in the current version of the monograph "Products with Risk of Transmitting Agents of Animal Spongiform Encephalopathies No. 1483 of the European Pharmacopoeia.


This Certificate of Suitability now enables Bovogen Biologicals foetal bovine serum to be used for the manufacture of medicines in the European Union. This certification compliments company's existing EDQM certification for its range of bovine serum albumin (BSA) products manufactured in Australia using raw materials of Australian origin only. See Bovogen Biological for more information on foetal bovine serum (FBS).


December 17, 2006
Fibrinogen Launched

Bovogen Fibrinogen

Bovogen Biologicals completed a series of process trials for the extraction and purification of bovine fibrinogen from bovine blood serum. Large scale production was subsequently initiated and a fibrinogen product with excellent solubility, stability, high clotting properties was commecially available in December, 2006.

For more information contact Bovogen Biologicals.  

 


May 26, 2006
EDQM Certificate Granted

Certificate of Suitability Granted

Bovogen Biologicals received a Certificate of Suitability from the European Directorate of Quality Medicines for it's range of bovine serum albumin products in May, 2006. This certification meets the criteria described in the current version of the monograph "Products with Risk of Transmitting Agents of Animal Spongiform Encephalopathies No. 1483 of the European Pharmacopoeia.

This Certificate of Suitability also covers some of the components used in the manufacture of at least one type of BSA product manufactured by Bovogen Biologicals.

For more information contact Bovogen Biologicals.    


May 5, 2006
Industry Award

Bovogen Biologicals receives Award

Bovogen Biologicals received an Australian Red Meat Industry Award for Innovation following nomination and selection from a number of Australian bioactives manufacturers by an independant industry panel. The award was for the development of a novel bovine serum albumin product called 'BovoLep' which has been shown by industry to enhance the growth of fastidious micro-organisms such as Leptospira. BovoLep BSA has also been shown to be a superior product to other BSAs when used as a supplement in serum free mammalian cell culture systems.

Managing Director, Rick Clements, accepted the award on behalf of Bovogen Biologicals at the Australian Red Meat Industry conference dinner in Rockhampton, Queensland in May, 2006.

For more information conatct Bovogen Biologicals. 


November 17, 2005
EU and Taiwan Listings

Blood Products Listed Overseas

Bovogen Biologicals is granted blood products export listing for the EU and Taiwan by the Australian Quarantine Inspection Service (AQIS). This enables the company to export blood products to these destinations following audit and approval by AQIS.

For more information conatct Bovogen Biologicals. 


August 17, 2005
Foetal Bovine Serum

FBS Production Begins

Bovogen Biologicals has added foetal bovine serum (FBS) to it's product portfolio. Using only Australian sourced foetal bovine blood, the company commenced manufacture of an FBS product of exceptional quality which  has been  promoted both domestically and internationally by Bovogen's network of distributors and agents.

For more information contact Bovogen Biologicals. 


March 17, 2005
Biovine Biologicals Formed

Bovine Biologicals  

Managing Director of Bovogen Biologicals, Rick Clements teams up with Dr. David Kennedy from Biotechnology Development Ltd. to form and register a new company called Biovine Biologicals Pty Ltd.

Biovine Biologicals shall focus on the development and supply of ovine proteins and related products for the life science industries. Australia is one of a relative few countries that is scrapie free (ovine form of a transmissable spongiform encephalopathy) hence, making the country an excellent source of ovine biological products. Australia's abundant sheep herds also facilitates the sourcing of inexpensive raw materials.  

Certain ovine blood clotting proteins shall also be developed and manufactured by Bovogen Biologicals on behalf of Biovine Biologicals for the development of haemostasis applications by international collaborators.

Biovine Biologicals' ovine based products shall also provide an alternative to traditional bovine sourced compounds hence, providing global life science industries with products that are not affected by BSE concerns.

For more information conatct Bovine Biologicals. 

 


July 17, 2004
BovoLep BSA Production

BovoLep Production Begins

Through market research, Bovogen Biologicals discovered that animal pharmaceutical manufacturers using BSA for the growth of a variety of micro-organism derived vaccines were constantly frustrated at the variability in the performance of cultures. Through development work with industry partners and customers, Bovogen developed a non-animal, synthetic lipid fortified BSA product  that demonstated advantages such as process and yield consistency, enhanced product yield and lipid content consistency. BovoLep BSA was also shown to be a far superior product in serum free mammalian culture systems when compared to traditional BSA products.

As a result of this collaboratoive effort, Bovogen commenced production of BovoLep BSA in mid-2004. 

For more information conatct Bovogen Biologicals.  

 


December 17, 2003
Large Scale BSA Production

BSA Production Begins

Bovogen Biologicals commenced large scale BSA production in the last quarter of 2003 following the completion of commissioning and validation of it's manufacturing facility.

For more information conatct Bovogen Biologicals.


August 17, 2002
BSA Production Trial

Trial Begins 

Bovogen Biologicals commenced pilot phase trials of it's BSA manufacturing process during the course of 2002. Process parameters were developed, process control systems were implemented and large scale facility design was initiated.

For more information contact Bovogen Biologicals.




Archives